Javier Gorricho1, Javier Garjón2, Alvaro Alonso3, María Concepción Celaya2, Luis Carlos Saiz2, Juan Erviti2, Antonio López2. 1. Planning, Evaluation and Management Service, General Directorate of Health, Government of Navarre, Calle Irunlarrea 3 (Pabellón Docencia del Hospital de Navarra), 31008, Pamplona, Navarre, Spain. 2. Subdirectorate of Pharmacy, Navarre Regional Health Service, Plaza de la Paz s/n, 31002, Pamplona, Navarre, Spain. 3. Rollins School of Public Health, Emory University, 1518 Clifton Road, NE, Atlanta, GA 30322, USA.
Abstract
AIMS: To evaluate the association between use of different oral antidiabetic agents (OAD) and the risk of community-acquired pneumonia (CAP) in patients with type-2 diabetes (T2DM). METHODS: Case-control study nested in a cohort of patients with T2DM and use of OAD between 2002 and 2013, based in a Spanish general practice research database. Cases were people diagnosed with T2DM, aged >18 years and with a validated diagnosis of CAP between 2002 and 2013. Ten controls were matched on age, sex and calendar year. Odds ratio (OR) of CAP was estimated comparing patients treated with: (1) metformin vs. other monotherapies or no antidiabetic treatment; (2) metformin + sulfonylureas vs. other antidiabetic combinations. OR of CAP was also assessed according to antidiabetic treatment duration. RESULTS: From a cohort of 76 009 T2DM patients, we identified 1803 cases of CAP. No difference in the incidence of CAP was observed when comparing any OAD in monotherapy with metformin. Compared with current use of metformin + sulfonylurea, thiazolidinediones + metformin was associated with an increased risk of CAP (adjusted OR = 2.48, 95% CI 1.40-4.38). The use of any combination with thiazolidinediones was also associated with higher risk of CAP (adjusted OR = 2.00, 95% CI 1.22-3.28). Current use of DPP-4 inhibitors was not associated with an increased risk of CAP. CONCLUSIONS: No differences in the incidence of CAP were observed between the use of OAD in monotherapy vs. metformin. Thiazolidinedione use in combination was associated with an increase in the risk of CAP when compared to metformin + sulfonylureas. The use of DPP-4 inhibitors was not associated with an increased risk of CAP.
AIMS: To evaluate the association between use of different oral antidiabetic agents (OAD) and the risk of community-acquired pneumonia (CAP) in patients with type-2 diabetes (T2DM). METHODS: Case-control study nested in a cohort of patients with T2DM and use of OAD between 2002 and 2013, based in a Spanish general practice research database. Cases were people diagnosed with T2DM, aged >18 years and with a validated diagnosis of CAP between 2002 and 2013. Ten controls were matched on age, sex and calendar year. Odds ratio (OR) of CAP was estimated comparing patients treated with: (1) metformin vs. other monotherapies or no antidiabetic treatment; (2) metformin + sulfonylureas vs. other antidiabetic combinations. OR of CAP was also assessed according to antidiabetic treatment duration. RESULTS: From a cohort of 76 009 T2DM patients, we identified 1803 cases of CAP. No difference in the incidence of CAP was observed when comparing any OAD in monotherapy with metformin. Compared with current use of metformin + sulfonylurea, thiazolidinediones + metformin was associated with an increased risk of CAP (adjusted OR = 2.48, 95% CI 1.40-4.38). The use of any combination with thiazolidinediones was also associated with higher risk of CAP (adjusted OR = 2.00, 95% CI 1.22-3.28). Current use of DPP-4 inhibitors was not associated with an increased risk of CAP. CONCLUSIONS: No differences in the incidence of CAP were observed between the use of OAD in monotherapy vs. metformin. Thiazolidinedione use in combination was associated with an increase in the risk of CAP when compared to metformin + sulfonylureas. The use of DPP-4 inhibitors was not associated with an increased risk of CAP.
Authors: Stephen Ph Alexander; Anthony P Davenport; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739
Authors: A Ruigómez; R Brauer; L A García Rodríguez; C Huerta; G Requena; M Gil; Francisco de Abajo; G Downey; A Bate; M Feudjo Tepie; M de Groot; R Schlienger; R Reynolds; O Klungel Journal: Eur J Clin Pharmacol Date: 2014-07-29 Impact factor: 2.953
Authors: Samuel S Engel; Elizabeth Round; Gregory T Golm; Keith D Kaufman; Barry J Goldstein Journal: Diabetes Ther Date: 2013-05-23 Impact factor: 2.945
Authors: Rogier Wvan der Zanden; Frank de Vries; Arief Lalmohamed; Johanna H M Driessen; Anthonius de Boer; Gernot Rohde; Cees Neef; Casper den Heijer Journal: PLoS One Date: 2015-10-15 Impact factor: 3.240
Authors: Stephen Ph Alexander; John A Cidlowski; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739
Authors: Christopher Southan; Joanna L Sharman; Helen E Benson; Elena Faccenda; Adam J Pawson; Stephen P H Alexander; O Peter Buneman; Anthony P Davenport; John C McGrath; John A Peters; Michael Spedding; William A Catterall; Doriano Fabbro; Jamie A Davies Journal: Nucleic Acids Res Date: 2015-10-12 Impact factor: 16.971
Authors: Jette B Kornum; Reimar W Thomsen; Anders Riis; Hans-Henrik Lervang; Henrik C Schønheyder; Henrik T Sørensen Journal: Diabetes Care Date: 2008-05-16 Impact factor: 19.112
Authors: Jiandong Zhou; Guoming Zhang; Carlin Chang; Oscar Hou In Chou; Sharen Lee; Keith Sai Kit Leung; Wing Tak Wong; Tong Liu; Abraham Ka Chung Wai; Shuk Han Cheng; Qingpeng Zhang; Gary Tse Journal: Acta Diabetol Date: 2022-02-03 Impact factor: 4.280
Authors: John-Michael Gamble; Jennifer R Donnan; Eugene Chibrikov; Laurie K Twells; William K Midodzi; Sumit R Majumdar Journal: Sci Rep Date: 2018-10-11 Impact factor: 4.379
Authors: Loreto Arias Fernández; Jacobo Pardo Seco; Miriam Cebey-López; Ruth Gil Prieto; Irene Rivero-Calle; Federico Martinon-Torres; Ángel Gil de Miguel; F Martinón-Torres; D Vargas; E Mascarós; E Redondo; J L Díaz-Maroto; M Linares-Rufo; A Gil; J Molina; D Ocaña; I Rivero-Calle Journal: BMC Infect Dis Date: 2019-11-15 Impact factor: 3.090